Researchers at Leipzig University found that bovine cells exhibit significant similarities to human cells, particularly in how they undergo programmed cell death.

This discovery could change how scientists develop new medications. By using bovine cells instead of other animal models, researchers may be able to more accurately predict how a drug will behave in the human body, potentially reducing the failure rate of new treatments.

The study focuses on apoptosis, the process of programmed cell death. Veterinary researchers at Leipzig University said that bovine cells more closely resemble human cells than mouse cells do in this regard. This distinction is critical because the mechanisms that trigger or stop cell death are often the primary targets for treating various diseases.

For decades, the scientific community has relied heavily on rodents for preliminary testing. "Mouse cells are commonly used to test potential drug candidates," the researchers said. However, the differences between rodent and human cellular responses can lead to results that do not translate to human patients during clinical trials.

By leveraging the biological proximity of bovine cells, scientists aim to explore the manipulation of apoptosis to treat diseases such as cancer. The research suggests that bovine models could provide a more reliable bridge between laboratory experiments and human application, a shift that could accelerate the timeline for drug approval.

The team at the German university continues to analyze these cellular pathways to determine exactly which bovine proteins most closely mirror human counterparts. This work may eventually lead to a broader shift in veterinary and human medical research protocols.

“bovine cells more closely resemble human cells than mouse cells do”

The shift toward bovine models represents a potential pivot in pharmacology. If cow cells provide a more accurate biological mirror for human apoptosis than mouse cells, the pharmaceutical industry could reduce its reliance on rodent models, potentially lowering the cost and risk of drug development by identifying ineffective compounds earlier in the process.